Therapeutic Effect of Danazol on Metrorrhagia in Patients with Idiopathic Thrombocytopenic Purpura (ITP)

Ambríz, F.; Pizzuto, J; Morales, M.; Chávez, Gonzalo; Guillén, C.; Avilés, Agustín

doi:10.1097/00006254-198711000-00017

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Danazol can also suppress menses effectively, providing additional benefit to women who have clinically significant menometrorrhagia. Moreover, as reported previously, 28 we noticed improvement in hemorrhagic symptoms even in nonresponders, suggesting the favorable effects of danazol on vessel wall integrity.…”

Section: Discussionsupporting

confidence: 91%

The Effect of Danazol in Primary Immune Thrombocytopenia

Liang

et al. 2016

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

The Effect of Danazol in Primary Immune Thrombocytopenia

Liang

et al. 2016

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…lications on danazol in ITP [9][10][11][12][13][14][15][16][17][18][19][20], 9 of which con firmed our findings [9][10][11][12][13][14][15][16][17], but 3 described negative results [18][19][20], In all 3, the duration of therapy was limited to 2-3 months, i.e. inadequate for a full evalu ation.…”

supporting

confidence: 69%

Efficacy of Danazol in Hematologic Disorders

Ahn¹

1990

Acta Haematol

View full text Add to dashboard Cite

Danazol, an attenuated androgen developed for the treatment of endometriosis, has recently been found useful in the treatment of several hematologic disorders, including idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, and others. Our studies of the past 6 years have demonstrated that danazol is advantageous in the treatment of AIHA, and in specifically defined populations of ITP patients. Of 96 ITP patients treated with danazol 61% overall had excellent/good responses, but this rate varied markedly with prognostic factors, e.g. 82% in older women versus only 18% in younger women. Of 28 AIHA patients, 77% with idiopathic type and 60% with secondary type were excellent/good responders. When the drug was discontinued after 1 year or more of therapy, lasting unmaintained remissions of up to 5 years were often observed in both ITP and AIHA, a notably important benefit. The side-effects of danazol are generally much less serious than with glucocorticoids. Glucocorticoids can be tapered off and in most cases discontinued completely with danazol therapy in AIHA and chronic ITP. Approximately one third of ITP patients who failed on glucocorticoids are successfully maintained on danazol. Its mechanism of action in these disorders is currently under study in our laboratory, stimulated by new findings. Tentatively, danazol appears to modify cell membranes in a manner leading to specific immune modulations, as discussed. Further study is warranted to explore its application to other autoimmune and membrane-related disorders, and to clarify its mechanism of therapy.

show abstract

“…1 ). Six studies were prospective, [ 15 , 18 , 20 , 28 , 30 , 35 ] and 2 studies included consecutive series of patients. [ 8 , 21 ] Individual data were available for 21 studies that included 279 patients.…”

Section: Resultsmentioning

confidence: 99%

Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura

et al. 2017

View full text Add to dashboard Cite

BackgroundCorticosteroid sparing is required in 15% to 40% of adults with persistent or chronic primary immune thrombocytopenic purpura (ITP). Herein, the efficacy of immunomodulatory drugs (dapsone, interferon alpha, danazol, and hydroxychloroquine as second-third-line therapies in ITP is investigated.MethodsMEDLINE was searched for studies that included patients with persistent or chronic primary ITP and published before the end of December 2014. Two investigators independently extracted data regarding study design, patient characteristics, dosage schedule, time to response, and occurrence of adverse events. The pooled overall response rate (ORR; platelet count >30 × 109 L−1) and the complete response rate (CRR; platelet count >100 × 109 L−1) were evaluated to determine drug efficacy by calculating weighted mean proportion using a fixed or random-effects model according to heterogeneity (I2 > 50%). The study was performed following the MOOSE and PRISMA guidelines.ResultsA total of 28 studies (415 patients) were included (dapsone: k = 7 studies, n = 80; danazol: k = 12, n = 224; interferon alpha: k = 8, n = 83; hydroxychloroquine: k = 1, n = 28). The mean patient age was 50 years (female sex 70%, splenectomy 47%). The ORR and CRR were 55% (95% CI: 44%–66%, I2 = 0%) and 21% (95% CI: 13%–31%, I2 = 0%), respectively, for dapsone; 42% (95% CI: 22%–65%, I2 = 63%) and 18% (95% CI: 10%–29%, I2 = 9%), respectively, for interferon alpha; and 58% (95% CI: 42%–72%, I2 = 67%) and 29% (95% CI: 19%–42%, I2 = 63%), respectively, for danazol. The ORR was 50% (95% CI: 32%–67%) for hydroxychloroquine (data not available for CRR). Meta-regression analysis found a correlation between the ORR for interferon alpha and the splenectomized status of the patient (P = .02) and between the CRR for danazol and disease duration (P < .001). In total, 73%, 51%, 30%, and 0% of patients who received danazol, dapsone, interferon alpha, and hydroxychloroquine experienced side effects, respectively.ConclusionThe ORR was equivalent for hydroxychloroquine, danazol, and dapsone in ITP. Regarding their low CRR, patients at high risk of infection or at low risk of bleeding should benefit from these treatments. Thanks to their best efficacy and safety profiles, dapsone and hydroxychloroquine in patients with antinuclear antibodies should be preferred over danazol and interferon alpha.

show abstract

Therapeutic Effect of Danazol on Metrorrhagia in Patients with Idiopathic Thrombocytopenic Purpura (ITP)

Cited by 7 publications

References 0 publications

The Effect of Danazol in Primary Immune Thrombocytopenia

The Effect of Danazol in Primary Immune Thrombocytopenia

Efficacy of Danazol in Hematologic Disorders

Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura

Contact Info

Product

Resources

About